The actual data presentations at ESMO (likely September/October 2026) will be the key catalyst. Monitor for efficacy and safety updates that could materially move the stock. No immediate trading action warranted.
Price Chart
Executive Summary
Eikon Therapeutics announced that seven abstracts covering its pipeline (EIK1001, EIK1003, EIK1004, EIK1005) have been accepted for presentation at the 2026 ESMO Congress. No clinical data or financial results were disclosed in this press release; the actual data readouts will occur at the conference.
Key Facts
- Seven abstracts accepted for ESMO 2026 across four pipeline programs
- Abstracts include updated Phase 2 data for EIK1001 (TLR7/8 agonist) in NSCLC, initial Phase 1/2 data for EIK1003 (PARP1 inhibitor) combinations, initial Phase 1/2 data for EIK1004 (CNS-penetrant PARP1 inhibitor), and initial safety/PK data for EIK1005 (WRN helicase inhibitor)
- No financial figures, revenue, EPS, or guidance were provided
Financial Impact
No financial impact disclosed; this is a pipeline update announcement without data results.
Risk Factors
- Clinical trial data may fail to meet expectations
- Pipeline setbacks could negatively impact valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3329652 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 26, 2026 today | Press Release | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 23, 2026 3d ago | 8-K | $8.01 | awaiting T+20 | — | $6.68 (−16.57%) |
Oct 7, 2026 18d ago | SC 13G/A | $7.54 | awaiting T+20 | — | $6.68 (−11.37%) |
Oct 2, 2026 23d ago | SC 13G/A | $7.33 | awaiting T+20 | — | $6.68 (−8.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $8.98 $8.18 | ▼ −8.91% | ▼ −8.35% | $6.68 (−25.58%) |
Sep 8, 2026 6w ago | Insider Buy | $10.73 $7.54 | ▼ −29.73% | ▼ −31.67% | $6.68 (−37.72%) |
Sep 3, 2026 7w ago | Press Release | $10.96 $8.04 | ▼ −26.64% | ▼ −25.52% | $6.68 (−39.03%) |
Aug 13, 2026 10w ago | 8-K | $11.05 $9.36 | ▼ −15.29% | ▼ −13.30% | $6.68 (−39.52%) |
Jul 20, 2026 14w ago | Press Release | $9.65 $10.47 | ▲ +8.50% | ▲ +4.38% | $6.68 (−30.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers